Purpose: The epidermal growth factor receptor (EGFR) is abnormally activated in cancer
and two classes of anti-EGFR agents, monoclonal antibodies and low-molecular-weight …

BACKGROUND AND PURPOSE: The epidermal growth factor receptor (EGFR) is
overexpressed in a significant percentage of human malignancies and its expression is …

Epidermal growth factor receptor (EGFR) over-signaling leads to more aggressive tumor
growth. The antitumor effect of Cetuximab, an anti-EGFR antibody, depends on oncogenic …

Chemotherapy alone has limited ability to significantly improve survival in non-small lung
cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor …

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is part of
the family of tyrosine kinase receptors. The binding of EGFR to its cognate ligands leads to …

Purpose To investigate whether mRNA expression levels of cyclin D1 (CCND1),
cyclooxygenase 2 (Cox-2), epidermal growth factor receptor (EGFR), interleukin 8 (IL-8), and …

Objectives: Non-melanoma skin cancer is the most common malignancy in US, with an
annual incidence of in excess of 1.5 million cases. In the majority of cases, locoregional …

Epidermal growth factor receptor (EGFR) is frequently overexpressed in epithelial tumors
and is associated with a poor prognosis. An increasing interest in developing anti-EGFR …

Monoclonal antibody (mAb) 806 is a novel epidermal growth factor receptor (EGFR)
antibody with significant antitumor activity that recognizes a mutant EGFR commonly …

Purpose: Acquired resistance to cetuximab, a chimeric epidermal growth factor receptor
(EGFR)–targeting monoclonal antibody, is a widespread problem in the treatment of solid …